LeMaitre Vascular (NASDAQ:LMAT) Reaches New 1-Year High – What’s Next?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $116.50 and last traded at $116.3960, with a volume of 7931 shares trading hands. The stock had previously closed at $114.62.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LMAT. Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Wells Fargo & Company increased their target price on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 26th. Roth Mkm reiterated a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Citizens Jmp increased their target price on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Finally, Barrington Research increased their target price on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $105.80.

LeMaitre Vascular Stock Performance

The company has a market cap of $2.68 billion, a P/E ratio of 46.80, a price-to-earnings-growth ratio of 3.30 and a beta of 0.67. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average price of $102.43 and a two-hundred day moving average price of $91.59.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The company had revenue of $64.45 million for the quarter, compared to analyst estimates of $62.98 million. During the same quarter last year, the company earned $0.49 earnings per share. The firm’s quarterly revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were paid a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date was Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is 39.84%.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 1,044 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $110.29, for a total transaction of $115,142.76. Following the transaction, the insider owned 6,677 shares in the company, valued at $736,406.33. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO George W. Lemaitre sold 150,000 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $106.76, for a total value of $16,014,000.00. Following the transaction, the chief executive officer owned 1,532,304 shares in the company, valued at approximately $163,588,775.04. This trade represents a 8.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 215,438 shares of company stock worth $23,062,911 in the last 90 days. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds have recently added to or reduced their stakes in the stock. Vest Financial LLC raised its position in LeMaitre Vascular by 60.0% during the third quarter. Vest Financial LLC now owns 56,279 shares of the medical instruments supplier’s stock valued at $4,925,000 after purchasing an additional 21,102 shares in the last quarter. SG Americas Securities LLC acquired a new position in LeMaitre Vascular during the third quarter valued at approximately $1,101,000. Congress Asset Management Co. raised its position in LeMaitre Vascular by 5.8% during the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after purchasing an additional 40,065 shares in the last quarter. Public Sector Pension Investment Board increased its stake in shares of LeMaitre Vascular by 15.8% in the 3rd quarter. Public Sector Pension Investment Board now owns 81,211 shares of the medical instruments supplier’s stock valued at $7,107,000 after purchasing an additional 11,092 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in shares of LeMaitre Vascular in the 3rd quarter valued at $6,056,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.